4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Myopia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 117 ongoing clinical trials involving Myopia
Of the 117 trials,38 trials are in Phase II
Furthermore, 29 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Myopia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Myopia, an ophthalmology indication. The largest number of ongoing clinical trials for Myopia is conducted in Europe. Asia-Pacific and North America are among some of the other prominent regions engaged in Myopia-related drug trials.

Beijing Tongren Hospital: The leading ongoing Myopia related clinical trial sponsor

Beijing Tongren Hospital is the top sponsor for Myopia-related ongoing clinical trials.

Sun Yat-sen University, Sun Yat-sen University, Capital Medical University, and Tokyo Medical and Dental University are among other notable clinical trial sponsors involved in Myopia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Myopia

Aflibercept (Eylea), Atropine Sulfate (Eikance), and Homatropine methylbromide (Omatropina Lux) are among the key marketed drugs involving Myopia.

Aflibercept (Eylea) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. It functions via Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Inhibitor; Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor mechanism of action. Eylea is formulated as an iso-osmotic injection solution for intravitreal route of administration. Eylea is indicated for treatment of neovascular (wet) age-related macular degeneration (wet AMD) and for the treatment of macular edema following central retinal vein occlusion. It is also indicated for diabetic macular edema (DME) and Diabetic Retinopathy (DR) in Patients with DME, for the treatment of choroidal neovascularization and macular edema secondary to branch retinal vein occlusion (BRVO), for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV), and all stages of non-proliferative diabetic retinopathy (DR), and thereby reduce the risk of blindness. Aflibercept was first approved in 2011 and is marketed globally including the US, the UK, France, and Germany by Regeneron Pharmaceuticals Inc, and Bayer AG.

Atropine Sulfate (Eikance) is an alkaloid acts as as a cycloplegic and mydriatic agent obtained from Atropa belladonna belongs to anti-cholinergic agent. It functions via Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Antagonist mechanism of action. It is formulated as tablets for oral route of administration and solution drops for ophthalmic route of administration. Atropt is indicated where it is necessary to dilate the pupil and paralyse accommodation. Eikance is indicated as a treatment to slow the progression of myopia in children aged from 4 to 14 years. Atropine Sulfate was first approved in 1972 and is marketed in Australia by Aspen Pharma Pty Ltd.